Warp Sciences raises $215 million to robotize laboratory work

Training robots on lab work

Biotechnology companies have long outsourced one of drug development’s most labor-intensive steps: synthesizing thousands of molecular variants. Some have relied on Chinese contractors such as WuXi AppTec.

Warp Sciences’ chemists will wear cameras and gloves fitted with sensors as they perform laboratory tasks. The company intends to use that data to teach robots to handle real samples. Robots, unlike human staff, could work around the clock.

The $215 million round was led by Lightspeed, with IVP, Premji Invest and Lux Capital also participating.

The harder part is proving the loop

I think the more consequential claim here is the plan to bring synthesis back to the US, not the promise of round-the-clock robots. Capturing how chemists work is a start; the announcement does not say how many tasks the robots can perform, or how reliably they can handle them.

That leaves the central question unanswered: how much of the synthesis process can Warp Sciences automate before human chemists must step back in? The answer will determine whether this is a new way to run a lab—or a costly layer of robotics around work that still depends on people.